论文部分内容阅读
骨髓增生异常综合征(MDS)是一组起源于造血干细胞(HSC)的异质性克隆性疾患,以形态学改变(病态造血)和造血功能异常(无效造血)为主要特征,然而其发生、发展及白血病转化的分子机制尚不明确。MicroRNA(miRNA)是一类重要的非编码小分子RNA,在调控造血干细胞发育进程中起着重要作用,其在MDS的发生发展及白血病转化中的作用也逐渐被认识,以miRNA为分子靶点诊治造血干细胞受损疾患的研究具有广阔的应用前景。
Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal disorders stemming from hematopoietic stem cells (HSCs). Morphological changes (pathological hematopoiesis) and hematopoietic dysfunction (ineffective hematopoiesis) are the main features. However, their occurrence, The molecular mechanism of development and leukemia conversion is not clear. MicroRNAs (miRNAs) are important non-coding small RNAs which play an important role in the regulation of hematopoietic stem cell development. Their roles in the development of MDS and the transformation of leukemia have also been gradually recognized, and miRNAs as molecular targets Diagnosis and treatment of impaired hematopoietic stem cell disease has broad application prospects.